Gu et al. (2019) discovered that HMGB3 silencing inhibited BC growth by interacting with HIF-1α. In addition, HMGB3 is correlated with treatment resistance. Li Z et al. (2020b) demonstrated that HMGB3 enhanced radioresistance by binding to the promoter region of hTERT in cervical cancer and suggested that targeting the HMGB3/hTERT axis might help cervical cancer patients who suffer from radioresistance. In ovarian cancer, Mukherjee et al. (2019) suggested that HMGB3 depletion might sensitize chemoresistant cancer cells to cisplatin through the ATR/CHK1/p-CHK1 DNA damage signaling pathway. Here, CHEK1 is linked to ovarian cancer.